India’s Leap from Generics to Novel Drug Discovery: Building a Global Innovation Hub

India’s pharmaceutical industry has long been recognised as the pharmacy of the world, supplying affordable generic medicines to patients across continents. That foundation remains strong, yet a more ambitious chapter is now taking shape. The sector is steadily moving beyond high-volume manufacturing of known molecules toward original drug discovery, advanced therapies and intellectual-property creation. Artificial intelligence, biotech start-ups and new therapeutic platforms are accelerating this shift, while policy support and private capital begin to align around a longer-term vision of innovation-led growth.

The scale of the existing industry provides a powerful base. India ranks third globally by production volume and eleventh by value. It accounts for roughly one-fifth of the world’s generic medicine supply and manufactures tens of thousands of brands across dozens of therapeutic categories. This manufacturing strength has delivered both domestic access and substantial export earnings. The next phase, however, requires converting that operational excellence into scientific ownership of new medicines.

A Clear Call for Global Ambition

In his Independence Day address in 2026, the Prime Minister underscored this aspiration by stating that one or two Indian pharmaceutical companies should establish themselves among the world’s top five. The remark was both an acknowledgement of progress already made and a challenge to raise the ceiling of ambition. As India advances toward the broader national goal of Viksit Bharat by 2047, a robust drug-discovery and development ecosystem is increasingly viewed as essential for scientific advancement, economic value creation and the delivery of life-saving treatments.

Evidence of the Emerging Shift

Several indicators confirm that the transition is under way. Private equity and venture capital investment directed at pharmaceutical innovation has more than doubled over five years, reaching approximately 731 million dollars in the most recent financial year. The number of biotech start-ups has grown from around 1,500 a decade ago to roughly 2,400. India’s drug-discovery pipeline now exceeds 1,095 programmes across nearly 200 companies. Patent families originating from India in the pharmaceutical domain have risen sharply, lifting the country’s share of global pharmaceutical patents toward 10 per cent.

More than ten novel drug assets of Indian origin have emerged over the past decade and a half. These include first-in-class therapies, indigenous CAR-T cell treatments for blood cancers, AI-discovered molecules and novel antibiotics that have secured regulatory attention in major markets. Licensing agreements with global partners and the commercialisation of advanced therapies at significantly lower cost than international benchmarks demonstrate that Indian science can compete on both quality and affordability.

The Role of Artificial Intelligence and Start-ups

Artificial intelligence is compressing timelines that once stretched across years. Algorithms can rapidly screen vast libraries of compounds, predict properties and shortlist candidates for laboratory testing. What previously required exhaustive experimental cycles can now be narrowed to a manageable set of leads within months. Indian start-ups are actively building platforms that combine generative design, retrosynthesis prediction and ADMET modelling, enabling faster and more cost-effective early-stage discovery.

Alongside AI-driven approaches, specialised biotech firms are advancing cell and gene therapies, targeted biologics and treatments for antimicrobial resistance. Several of these programmes have already moved into clinical development or secured manufacturing and commercialisation partnerships. The combination of computational power and wet-lab capability is gradually expanding India’s presence in higher-value segments of the global pharmaceutical value chain.

Persistent Gaps That Must Be Closed

Despite encouraging momentum, structural challenges remain. Deep-technology drug discovery still attracts limited venture funding relative to the capital intensity and long timelines involved. Industry–academia collaboration, while improving, remains thinner than in leading innovation ecosystems. Regulatory processes for novel modalities need greater speed and predictability if Indian assets are to compete effectively on global timelines.

These gaps are not insurmountable. Government initiatives such as the Promotion of Research and Innovation in the Pharma-MedTech Sector scheme and the Biopharma SHAKTI mission are designed to strengthen research infrastructure, support biologics and advanced therapies, and foster closer links between public research institutions and industry. Centres of excellence, shared facilities and targeted funding are beginning to address earlier bottlenecks in talent, equipment and translational capacity.

Building the Complete Ecosystem

Sustained progress will require coordinated action on three fronts. First, funding must deepen and become more patient, particularly for early-stage and high-risk programmes. Second, genuine collaboration between universities, research institutes and companies must expand so that scientific discoveries translate more efficiently into development candidates. Third, regulatory pathways for innovative therapies need to keep pace with scientific advances while maintaining rigorous safety standards.

When these elements reinforce one another, India can move from being primarily a cost-efficient manufacturer to a generator of original intellectual property and globally competitive therapies. The manufacturing base already in place provides a natural advantage for scaling successful discoveries. The growing pool of scientific talent, the expanding start-up community and the increasing availability of computational tools further strengthen the foundation.

A Strategic Opportunity for the Decade Ahead

The transformation under way is neither sudden nor guaranteed. It is the result of cumulative investments in science, manufacturing capability and policy direction. The Prime Minister’s call for Indian companies to rank among the world’s leading pharmaceutical firms sets a clear directional goal. Achieving it will depend on converting today’s promising pipeline into a steady stream of approved, commercially successful medicines that address both Indian and global health needs.

If funding deepens, collaboration intensifies and regulation becomes more agile, India is well positioned to establish itself as a meaningful contributor to the next generation of medical treatments. The journey from pharmacy to laboratory is already visible in the data, the start-ups and the emerging assets. The task now is to accelerate that journey with the scale, consistency and ambition required to turn early successes into lasting global leadership.

Read more – grammarthink.com